TAO Kinase inhibitor 1

Cat. No.: HY-112136

CAS No.: 850467-66-2

Molecular Formula: $C_{25}H_{24}N_2O_2$

Molecular Weight: 384.47

Target: MAP3K

Pathway: MAPK/ERK Pathway

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 62.5 mg/mL (162.56 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6010 mL	13.0049 mL	26.0098 mL
	5 mM	0.5202 mL	2.6010 mL	5.2020 mL
	10 mM	0.2601 mL	1.3005 mL	2.6010 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

TAO Kinase inhibitor 1 (compound 43) is a selective, ATP-competitive thousand-and-one amino acid kinases (TAOK) inhibitor with IC_{50}s of 11 to 15 nM for TAOK1 and 2, respectively. TAO Kinase inhibitor 1 delays mitosis and induces mitotic cell death[1].

IC_{50} & Target

The MAP3K (Mitogen Activated Protein Kinase Kinase Kinase) TAOK (Thousand-And-One Kinase)

In Vitro

TAO Kinase inhibitor 1 delays mitosis and induces mitotic cell death in centrosome amplified breast cancer cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Eur J Pharm Sci. 2020 Dec 1;155:105557.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Koo CY, et al. Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. Mol Cancer Ther. 2017 Nov;16(11):2410-2421.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA